SEC Form 4 · accession 0001209191-17-032213
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan K. Smith
Officer — EVP, Technical Oprations
Period of report
May 10, 2017
Accepted (ET)
May 12, 2017 · 7:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.09 | May 10, 2017 | A | 20,000 | A | — | May 9, 2027 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on May 10, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.